Biotech Firm Edison Oncology (EOHC.US) Files for $25 Million U.S. IPO at $8-$10 per Share

Stock News12-01

Clinical-stage biotech company Edison Oncology Holding has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC), aiming to raise up to $25 million. The company plans to offer 2.8 million shares priced between $8 and $10 per share, with a proposed listing on the New York Stock Exchange under the ticker "EOHC."

Edison Oncology specializes in developing small-molecule oncology drug candidates through formulation optimization, drug repurposing, and next-generation mechanism research. Its pipeline includes Phase 1-2a assets targeting ARID1A-mutated cancers, replication stress pathways, ErbB-driven tumors, and pediatric solid tumors. The company advances its programs via traditional and 505(b)(2) regulatory pathways, conducting early-stage studies to evaluate safety, pharmacokinetics, and preliminary antitumor activity.

Financial reports indicate the company generated $446,000 in revenue over the 12-month period ending September 30, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142515570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142515570","market":"sg","top_or_hot":-1,"title":"Biotech Firm Edison Oncology (EOHC.US) Files for $25 Million U.S. IPO at $8-$10 per Share","media":"Stock News","content":"<p>Clinical-stage biotech company Edison Oncology Holding has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC), aiming to raise up to $25 million. The company plans to offer 2.8 million shares priced between $8 and $10 per share, with a proposed listing on the New York Stock Exchange under the ticker \"EOHC.\"</p>\n<p>Edison Oncology specializes in developing small-molecule oncology drug candidates through formulation optimization, drug repurposing, and next-generation mechanism research. Its pipeline includes Phase 1-2a assets targeting ARID1A-mutated cancers, replication stress pathways, ErbB-driven tumors, and pediatric solid tumors. The company advances its programs via traditional and 505(b)(2) regulatory pathways, conducting early-stage studies to evaluate safety, pharmacokinetics, and preliminary antitumor activity.</p>\n<p>Financial reports indicate the company generated $446,000 in revenue over the 12-month period ending September 30, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Firm Edison Oncology (EOHC.US) Files for $25 Million U.S. IPO at $8-$10 per Share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Firm Edison Oncology (EOHC.US) Files for $25 Million U.S. IPO at $8-$10 per Share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-01 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clinical-stage biotech company Edison Oncology Holding has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC), aiming to raise up to $25 million. The company plans to offer 2.8 million shares priced between $8 and $10 per share, with a proposed listing on the New York Stock Exchange under the ticker \"EOHC.\"</p>\n<p>Edison Oncology specializes in developing small-molecule oncology drug candidates through formulation optimization, drug repurposing, and next-generation mechanism research. Its pipeline includes Phase 1-2a assets targeting ARID1A-mutated cancers, replication stress pathways, ErbB-driven tumors, and pediatric solid tumors. The company advances its programs via traditional and 505(b)(2) regulatory pathways, conducting early-stage studies to evaluate safety, pharmacokinetics, and preliminary antitumor activity.</p>\n<p>Financial reports indicate the company generated $446,000 in revenue over the 12-month period ending September 30, 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO","symbol_name":"Renaissance IPO ETF","start_time":0,"source_url":"","article_id":"1142515570","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142515570","pubTimestamp":1764574845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clinical-stage biotech company Edison Oncology Holding has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC), aiming to raise up to $25 million. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO":"Renaissance IPO ETF"},"translate_title":"生物技术公司Edison Oncology(EOHC.US)以每股8-10美元的价格申请2500万美元的美国IPO","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO":1},"content_text":"Clinical-stage biotech company Edison Oncology Holding has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC), aiming to raise up to $25 million. The company plans to offer 2.8 million shares priced between $8 and $10 per share, with a proposed listing on the New York Stock Exchange under the ticker \"EOHC.\"\nEdison Oncology specializes in developing small-molecule oncology drug candidates through formulation optimization, drug repurposing, and next-generation mechanism research. Its pipeline includes Phase 1-2a assets targeting ARID1A-mutated cancers, replication stress pathways, ErbB-driven tumors, and pediatric solid tumors. The company advances its programs via traditional and 505(b)(2) regulatory pathways, conducting early-stage studies to evaluate safety, pharmacokinetics, and preliminary antitumor activity.\nFinancial reports indicate the company generated $446,000 in revenue over the 12-month period ending September 30, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142515570","isCrawlerRequest":true}